

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NALOX-1 PHARMACEUTICALS, LLC,  
Petitioner,

v.

OPIANT PHARMACEUTICALS, INC.,  
Patent Owners.

---

Case No. IPR2019-00690  
U.S. Patent No. 9,468,747

---

**MANDATORY NOTICES OF  
PATENT OWNER OPIANT PHARMACEUTICALS, INC.**

Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Opiant Pharmaceuticals, Inc.

(“Opiant”) submits the following mandatory notices:

**I. Real Parties in Interest, 37 C.F.R. § 42.8(b)(1)**

Adapt Pharma Limited (“Adapt”) and Opiant and are the assignees, and Adapt Pharma Operations Limited, a wholly owned subsidiary of Adapt, is a limited exclusive licensee, of U.S. Patent No. 9,561,177 and U.S. Patent No. 9,775,838. Opiant is the assignee, and Adapt Pharma Operations Limited is a limited exclusive licensee, of U.S. Patent No. 9,211,253; U.S. Patent No. 9,468,747; and U.S. Patent No. 9,629,965.

Adapt is a wholly owned subsidiary of Emergent Acquisitions Limited. Emergent Acquisitions Limited is a wholly owned subsidiary of Emergent International Inc., which is a wholly owned subsidiary of Emergent BioSolutions Inc. Emergent BioSolutions Inc. is a publicly held company, and no publicly held company owns 10% or more of Emergent BioSolutions Inc.’s stock. Opiant is a publicly held company, and no publicly held company owns 10% or more of Opiant’s stock.

**II. Related Matters, 37 C.F.R. § 42.8(b)(2)**

Petitioner Nalox-1 Pharmaceuticals, LLC (“Nalox-1”) has filed the following related petitions for *inter partes* review:

U.S. Patent No.	Case No.
9,211,253	IPR2019-00685

U.S. Patent No.	Case No.
9,211,253	IPR2019-00686
9,211,253	IPR2019-00687
9,468,747	IPR2019-00688
9,468,747	IPR2019-00689
9,468,747	IPR2019-00690
9,561,177	IPR2019-00691
9,561,177	IPR2019-00692
9,561,177	IPR2019-00693
9,629,965	IPR2019-00694
9,629,965	IPR2019-00695
9,629,965	IPR2019-00696
9,775,838	IPR2019-00697
9,775,838	IPR2019-00698
9,775,838	IPR2019-00699

U.S. Patent No. 9,211,253; U.S. Patent No. 9,468,747; U.S. Patent No. 9,561,177; U.S. Patent No. 9,629,965; and U.S. Patent No. 9,775,838 are being asserted in *Adapt Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA, Inc., et al.*, Case 2:16-cv-07721-JLL-JAD (D.N.J.) (consolidated), filed October 21, 2016; and *Adapt Pharma Operations Ltd., et al. v. Perrigo UK FINCO Limited Partnership*, Case 2:18-cv-15287-JLL-JAD (D.N.J.), filed October 25, 2018.

Administrative matters that would be or could be affected by this proceeding include pending U.S. Patent Application Nos. 15/415,221; 15/494,270; and 16/131,641.

**III. Lead & Backup Counsel, 37 C.F.R. § 42.8(b)(3)**

Opiant designates the following counsel:

LEAD COUNSEL

Robert F. Green  
Reg. No. 27,555  
Green, Griffith & Borg-Breen LLP  
676 North Michigan Avenue  
Suite 3900  
Chicago, IL 60611  
Phone: (312) 883-8000  
Fax: (312) 883-8001  
rgreen@greengriffith.com

BACKUP COUNSEL

Jessica Tyrus Mackay  
Reg. No. 64,742  
Green, Griffith & Borg-Breen LLP  
676 North Michigan Avenue  
Suite 3900  
Chicago, IL 60611  
Phone: (312) 883-8000  
Fax: (312) 883-8001  
jmackay@greengriffith.com

A power of attorney appointing the foregoing counsel to transact all business in this proceeding is being submitted together with this mandatory notice information.

**IV. Service Information, 37 C.F.R. § 42.8(b)(4)**

Counsel for Opiant submits the following service information:

**Electronic mail address:** jmackay@greengriffith.com

**Postal mail address:** Jessica Tyrus Mackay  
GREEN, GRIFFITH & BORG-BREEN, LLP  
676 North Michigan Avenue  
Suite 3900  
Chicago, IL 60611

**Telephone number:** (313) 883-8000

Counsel for Opiant consents to electronic service by email at  
jmackay@greengriffith.com.

Date: March 12, 2019

Respectfully submitted,

/Jessica Tyrus Mackay /  
Jessica Tyrus Mackay (Reg. No. 64,742)  
GREEN, GRIFFITH & BORG-BREEN, LLP  
676 North Michigan Avenue  
Suite 3900  
Chicago, IL 60611  
(313) 883-8000  
jmackay@greengriffith.com

*Counsel for Patent Owner  
Opiant Pharmaceuticals, Inc.*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.